Towa Pharmaceutical Management
Management criteria checks 2/4
Towa Pharmaceutical's CEO is Itsuro Yoshida, appointed in Jun 1996, has a tenure of 29.42 years. total yearly compensation is ¥113.00M, comprised of 62.8% salary and 37.2% bonuses, including company stock and options. directly owns 2.96% of the company’s shares, worth ¥4.33B. The average tenure of the management team and the board of directors is 1.8 years and 4.4 years respectively.
Key information
Itsuro Yoshida
Chief executive officer
JP¥113.0m
Total compensation
| CEO salary percentage | 62.83% |
| CEO tenure | 29.4yrs |
| CEO ownership | 3.0% |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Towa Pharmaceutical's (TSE:4553) Dividend Will Be ¥40.00
Sep 26
Towa Pharmaceutical (TSE:4553) Will Pay A Dividend Of ¥40.00
Sep 09Towa Pharmaceutical (TSE:4553) Has Announced A Dividend Of ¥40.00
Aug 24Towa Pharmaceutical (TSE:4553) Has Announced A Dividend Of ¥40.00
Aug 09Towa Pharmaceutical (TSE:4553) Is Due To Pay A Dividend Of ¥40.00
Jul 25Towa Pharmaceutical (TSE:4553) Will Pay A Dividend Of ¥40.00
Jul 10Towa Pharmaceutical Co., Ltd.'s (TSE:4553) Intrinsic Value Is Potentially 20% Below Its Share Price
Jun 11Towa Pharmaceutical Co., Ltd.'s (TSE:4553) Price Is Right But Growth Is Lacking
May 15Towa Pharmaceutical's (TSE:4553) Upcoming Dividend Will Be Larger Than Last Year's
Mar 15A Look At The Intrinsic Value Of Towa Pharmaceutical Co., Ltd. (TSE:4553)
Mar 11Towa Pharmaceutical (TSE:4553) Is Increasing Its Dividend To ¥40.00
Feb 18Towa Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 15Benign Growth For Towa Pharmaceutical Co., Ltd. (TSE:4553) Underpins Its Share Price
Dec 25Is Towa Pharmaceutical (TSE:4553) A Risky Investment?
Nov 13Towa Pharmaceutical (TSE:4553) Will Pay A Dividend Of ¥30.00
Sep 05Towa Pharmaceutical (TSE:4553) Is Due To Pay A Dividend Of ¥30.00
Aug 15Fewer Investors Than Expected Jumping On Towa Pharmaceutical Co., Ltd. (TSE:4553)
Aug 03Towa Pharmaceutical's (TSE:4553) Earnings Are Weaker Than They Seem
Jul 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | JP¥21b |
| Jun 30 2025 | n/a | n/a | JP¥16b |
| Mar 31 2025 | JP¥113m | JP¥71m | JP¥19b |
Compensation vs Market: Itsuro's total compensation ($USD731.22K) is about average for companies of similar size in the JP market ($USD980.36K).
Compensation vs Earnings: Insufficient data to compare Itsuro's compensation with company performance.
CEO
Itsuro Yoshida (74 yo)
Mr. Itsuro Yoshida has been the President at Towa Pharmaceutical Co. Ltd. since June 1996. Mr. Yoshida joined Towa Pharmaceutical Co., Ltd.in May 1979 and served as its Manager of Accounting since May 198...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Representative Director | 29.4yrs | JP¥113.00m | 2.96% ¥ 4.3b | |
| Executive Officer and GM of Accounting & Finance Division | 1.8yrs | no data | no data | |
| Executive Officer & GM of Administration Division | 1.4yrs | no data | no data | |
| Operating Officer & GM of Human Resource Development Center | 1.8yrs | no data | no data | |
| Senior Exe. Officer & Div Manager of R&D Div and Unit Manager of Innovative Tech Research Unit | 1.8yrs | no data | no data | |
| Full time Audit & Supervisory Board & Director | no data | no data | 0.014% ¥ 20.8m | |
| Executive MD & Director | less than a year | no data | 0.010% ¥ 14.6m | |
| Senior Executive Officer & GM of Production Division | 1.8yrs | no data | no data | |
| Executive Officer | no data | no data | no data | |
| Executive Officer | no data | no data | no data |
Experienced Management: 4553's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Representative Director | 41.9yrs | JP¥113.00m | 2.96% ¥ 4.3b | |
| Full time Audit & Supervisory Board & Director | 8.4yrs | no data | 0.014% ¥ 20.8m | |
| Executive MD & Director | 2.4yrs | no data | 0.010% ¥ 14.6m | |
| Director | 1.4yrs | no data | 0.0073% ¥ 10.7m | |
| Independent Outside Director | 1.4yrs | no data | no data | |
| Independent Outside Director | 10.4yrs | no data | no data | |
| Independent Outside Director | 5.4yrs | no data | no data | |
| Independent Outside Director | 4.4yrs | no data | no data | |
| Director | 1.4yrs | no data | 0.0075% ¥ 11.0m |
Experienced Board: 4553's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 07:42 |
| End of Day Share Price | 2025/11/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Towa Pharmaceutical Co., Ltd. is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |